Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16176982 | 0.82 | LPL (0.36) | KDM4EALDH1A1LPLLIPGHTT | |
| SCHEMBL26621923 | 0.80 | LPL (0.41) | KDM4EALDH1A1HPGDLPLLIPG | |
| SCHEMBL12822400 | 0.80 | MEN1 (0.41) | KDM4EALDH1A1LPLLIPGMEN1 | |
| SCHEMBL12822237 | 0.80 | NFKB1 (0.40) | KDM4EALDH1A1LPLLIPGMEN1 | |
| SCHEMBL775018 | 0.79 | LPL (0.40) | KDM4EALDH1A1LPLLIPGKMT2A | |
| SCHEMBL18662581 | 0.79 | LPL (0.40) | KDM4EALDH1A1LPLLIPGKMT2A | |
| SCHEMBL774936 | 0.79 | ALDH1A1 (0.41) | KDM4EALDH1A1LPLLIPGHTT | |
| SCHEMBL17045815 | 0.78 | KMT2A (0.44) | KDM4EALDH1A1HTTMEN1KMT2A | |
| SCHEMBL12822172 | 0.77 | GPR55 (0.42) | LPLLIPG | |
| SCHEMBL774640 | 0.77 | LPL (0.38) | KDM4EALDH1A1LPLLIPGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394902-B2 | Pyridyldiamido transition metal complexes, production and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120071616-A1 | Pyridyldiamido Transition Metal Complexes, Production And Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071616-A1 | Pyridyldiamido Transition Metal Complexes, Production And Use Thereof | PNPO, PLPBP, PDXK | KDM4E 3869/4885ALDH1A1 1554/4885HPGD 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.